Effect of flumazenil on recovery from sevoflurane in patients received nerve block

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001509

Enrollment

Unknown

Registered

2011-09-09

Start date

2011-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients need to receive anesthetization

Interventions

1:Patients in group flumazenil receives 0.006mg/Kg flumazenil ,diluted to 5ml by saline

2:Patients in group control receives 5ml saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients in orthopaedic department; 2. ASA 1-2; 3. age18-50; 4. limbs surgery and analgesic by nerve block; 5. time duration of surgery: 1-3 hour

Exclusion criteria

Exclusion criteria: 1. patients using sedative/depressant or drugs with side effect of drowsiness or nause and vomiting; 2. allergic to flumazenil of sevolurane; 3. mental disease or cognitive dysfunction; 4. fever and infectious disease; 5. asthma and other congenital disease; 6. do not cooperate to anesthesia; 7. malignant hyperthermia history or family history; 8. pregnancy and lactation period; 9. eye or ear dysfunction.

Design outcomes

Primary

Measure	Time frame
MAC-awake;	—

Secondary

Measure	Time frame
time to open eyes on commend;time until spontanous respiration;concentration of ET-sevoflurane at opening eyes;time to extubation;time until date of birth recolection;	—

Countries

China

Contacts

Public ContactLiang Peng

liangpeng_world@hotmail.com+86 18980602201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026